EGFR Mutation Positive NSCLC Patients With Gefitinib and Thalidomide

Clinical trial NCT03341494 · UNKNOWN

Trial details

NCT number: NCT03341494
Sponsor: Fujian Cancer Hospital
Status: UNKNOWN
Phase: Phase 2
Study type: INTERVENTIONAL

NSCLC Stage IV Chemotherapy Effect

Start date: 2017-04-01
Primary completion: 2019-11-01
Enrollment: 128

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.